Jacobs Levy Equity Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-229,369
| Closed | -$4.32M | – | 1159 |
|
|
2024
Q4 | $4.32M | Buy |
+229,369
| New | +$4.32M | 0.02% | 455 |
|
|
2024
Q3 | – | Sell |
-224,908
| Closed | -$4.69M | – | 1023 |
|
|
2024
Q2 | $4.69M | Sell |
224,908
-209,505
| -48% | -$4.37M | 0.02% | 469 |
|
|
2024
Q1 | $6.39M | Buy |
434,413
+184,086
| +74% | +$2.71M | 0.03% | 378 |
|
|
2023
Q4 | $2.58M | Buy |
250,327
+3,247
| +1% | +$33.5K | 0.01% | 559 |
|
|
2023
Q3 | $1.94M | Buy |
247,080
+200,184
| +427% | +$1.57M | 0.01% | 558 |
|
|
2023
Q2 | $468K | Sell |
46,896
-109,048
| -70% | -$1.09M | ﹤0.01% | 831 |
|
|
2023
Q1 | $1.38M | Sell |
155,944
-57,137
| -27% | -$507K | 0.01% | 640 |
|
|
2022
Q4 | $2.34M | Buy |
213,081
+200,230
| +1,558% | +$2.2M | 0.02% | 524 |
|
|
2022
Q3 | $167K | Buy |
+12,851
| New | +$167K | ﹤0.01% | 945 |
|